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The primary outcome was the nonspecific outcome medically-attended acute respiratory illness (MAARI). Surveillance cultures were obtained on some of the children presenting with MAARI. Vaccine effectiveness estimates against a nonspecific outcome like MAARI are lower than compared to the efficacy estimates based on culture-positive influenza because the outcome includes respiratory syncytial virus illness and other acute respiratory illness against which the vaccine has no effect. Previous research has shown that incorporating surveillance culture results into the analysis yields estimates of vaccine efficacy against influenza that are closer to the estimates one gets in randomized studies based on culture-confirmed influenza illness [5, 6, 7] .
In this paper, we report on an analysis incorporating surveillance cultures to estimate the 
Materials and Methods
Field study 
Influenza surveillance
Central Texas influenza surveillance was performed as previously described [1, 2, 5] . In brief, 
Statistical analysis
The effectiveness of protection against MAARI and the efficacy of protection against cultureconfirmed influenza were computed using the basic equation V E = 1−RR, where RR is the ratio of the number of MAARI (estimated influenza) cases/ child-days in the vaccinated compared to the unvaccinated group. Our main interest was in the efficacy of LAIV-T, but estimates were also obtained for TIV and previously vaccinated in 1998-2001 (PREV), all three being compared to the unvaccinated group. Age-group specific values were computed for the two age groups 5-9 years and 10-18 years. Overall efficacy was computed by weighting the contributions of the age groups by the combined number of child-days at risk in the vaccinated and unvaccinated groups in each age group.
A child who began the season as either unvaccinated or previously vaccinated could be switched to the LAIV-T group or the TIV group once they got vaccinated in 2003. The childdays contributed by each child to each group was calculated taking the switch into account. To take the changing vaccine status into account and to integrate the surveillance cultures into the analysis, we grouped the data by week over the ten week period. If vaccination occurred before the day of MAARI, the child was counted as a vaccinated MAARI case. Otherwise, the child was counted as a previously vaccinated or unvaccinated MAARI case. Similarly, a child contributed child-days at risk to either the unvaccinated or the previously vaccinated group up until and if they received LAIV-T or TIV, after which they contributed child-days at risk to the appropriate vaccinated group. We assumed that multiple visits in a week were not independent. Only the first MAARI case in the week was included if a child had more than one MAARI presentation in that week. We denote vaccine effectiveness against MAARI as VE a .
To estimate the efficacy against culture-confirmed influenza illness, the expected number of influenza cases in each week for each age and vaccine group was estimated by multiplying the proportion of positive surveillance cultures in each age and vaccine group by the number of MAARI cases in that group [6] . For each week, the childday at risk contribution was computed by subtracting the expected number of influenza cases times half the time interval from the number at risk at the beginning of the interval to adjust the child-days at risk. Children who had positive cultures were considered to be no longer at risk for influenza and did not contribute further child-days at risk for the rest of the ten week period.
We computed two different estimates using the surveillance cultures. The first, denoted VE in , uses just the surveillance cultures from the SWHP members in the database. The second, denoted VE ex , uses the surveillances cultures from both the SWHP members and the non-SWHP children. The surveillance cultures from the SWHP members are called the internal validation set because we also have the MAARI data on these children, while the others are the external validation set. Confidence intervals were obtained using 2000 bootstrap samples [10] . The details are in the technical appendix.
Results
Vaccination, MAARI cases, and child-days at risk Table 2 shows the covariate distribution by vaccine status at the end of the study period. The potential confounder Group 1 is composed of diagnoses of chronic obstructive pulmonary disease (COPD) and allied diseases, including asthma (ICD-9-CM Codes 490-496). Group 2 consists of several dozen chronic and congenital conditions, including HIV infection. The distributions of COPD and other diseases were similar in the LAIV-T, the previously vaccinated, and the unvaccinated groups. The TIV group has a much higher percentage of COPD and other diseases than the other groups, so that the comparison with the unvaccinated group is not valid, because one would expect that a valid comparison group with risk factors contraindicating LAIV-T would likely have a higher baseline MAARI rate. We present the data on the TIV vaccinees here for completeness, with the results in the text, not the tables. Differences in the age group distribution by vaccine status is adjusted for by weighting the age groups in the estimates of overall efficacy as described in the methods.
The total number of MAARI cases during the study period was 1,807. After counting just one MAARI event per child in a week, the total number of MAARI cases was 1,702, with 5,144 children having no MAARI event, 1,011 having just one, 165 having just two, and 48 having just three. Table 3 contains the number of MAARI events, child-days at risk, and rate per 1,000 by age and vaccine status used in the analysis. Table 4 shows the influenza surveillance data and proportion of cultures positive by age and vaccine status at the time of culture. We checked whether all cultures in the SWHP main dataset were associated with MAARI cases. There are 157 cultures in the study period in the main dataset. For 140 of them there was a MAARI admit-day that exactly matched the cultureday. There were 17 children with cultures for whom the automatically compiled data set had no MAARI visits on the day of culture. The records reviewed by P.A. Piedra established that 14 of the children had clinic visits on the day of culture. Of these 14, 10 had visits associated with MAARI illness, and 4 did not. For the 10 children with MAARI visits, we recorded a MAARI event in the data set on the day of culture. For the four children whose visit was not a MAARI event and the three children with no recorded visit on the day of culture, we excluded the culture. Thus, for the analysis, there are 150 cultures, representing 8.8% of the MAARI cases in the main SWHP data set.
Cultures and positive cultures
There are 177 non-SWHP children with surveillance cultures, 147 of whom had cultures within the study period. Only one child had two cultures within the study period, the first of which was negative for influenza. We created a second record and include the second culture as an independent data point. Within the 10 week period of interest, there were then 148 cultures in the non-SWHP children.
Vaccine effectiveness against MAARI and influenza
The estimates of VE a , VE in , and VE ex are given in Table 5 . Overall effectiveness of LAIV-T against MAARI VE a is 0.26 (95% CI: 0.11,0.39). Overall efficacy against culture-confirmed influenza using just surveillance cultures from children in the SWHP database, VE in , is 0.56 (95% CI 0.24,0.84). Using surveillance cultures from both children in the SWHP database and those from the S & W clinic surveillance sites who were not in the SWHP, overall efficacy against culture-confirmed influenza is 0.56 (95% CI 0.32,0.75). The point estimates for VE in and VE ex are quite similar, but the confidence intervals using all of the surveillance cultures are narrower than those using just the surveillance cultures from SWHP, reflecting the higher precision conferred by the larger number of cultures. There is no evidence that being previ- Table 5 because of the concern that the unvaccinated group was not comparable to the group receiving TIV on important risk factors.
However, for completeness, we present the overall estimates here in the text. The estimate of the overall effectivenees of TIV against MAARI is −0.71, (95% CI −1.2, −0.25) and against culture-confirmed influenza using surveillance cultures from just children in the SWHP database is −1.5, (95% CI −2.7, −0.53).
Discussion
This analysis shows that the live-attenuated influenza vaccine was cross-protective against a drift The new H3N2 variant began spreading coincident with the beginning of administration of vaccine in mid-October. Under these circumstances it was not possible to administer second doses to the children aged 5-9 years who were receiving vaccine for the first time. We anticipated that most of these children would have been primed by natural infection in prior years negating the need for a second dose. Over 95% of the children received only one dose of LAIV-T or TIV.
Our unvaccinated group was not comparable to the TIV group and the numbers were small. 2003-2004 [11] in a retrospective cohort study of children aged 6-23 months and a case-control study in persons aged 50-74 years are not comparable to our observations in school aged children.
Analysis of the experience with TIV in Colorado in
Use of the surveillance cultures to estimate efficacy assumes that the decision to obtain a culture on a child is not related to whether he actually had true influenza. If this assumption is violated, then the estimates could be subject to selection bias [5, 7] . However, Scharfstein et al [7] showed that even if there were substantial and differential selection bias in the vaccinated and unvaccinated groups, the bias in the efficacy estimates using the surveillance cultures is minimal.
Live-attenuated vaccine would be a good candidate for stockpiling vaccines for a pandemic where one would expect a mismatch with the anticipated strain [12, 13, 14] . In the case of a pandemic, it will be important to be able to evaluate the efficacy of a mismatched vaccine. The use of the well-planned surveillance cultures combined with rapid tests could be an important method for field evaluation in the case of a pandemic.
To compute child-days at risk, we assumed everyone was at risk at the beginning of the study period. For each time interval τ , the child-days at risk in each stratum, d kντ , was computed as 7 × (n kντ − 0.5ρ kντ w kντ ), ν = 0, 1, k = 1, . . . , K. That is, we subtracted the expected number of influenza cases times half the time interval from the number at risk at the beginning of the interval to adjust the child-days at risk. Children who had positive cultures were considered to be no longer at risk for influenza and did not contribute further child-days at risk for the rest of the ten week period.
From this, we estimate the incidence rate of true influenza in each vaccine group, and from that, the group specific vaccine efficacy, VE k,v , based on the validation set as
Overall VE v is computed by weighting the contributions of the age groups by the combined number of child-days at risk in the vaccinated and unvaccinated groups in each age group.
Confidence intervals were based on the bootstrap [10] .
To estimate vaccine efficacy based on the SWHP surveillance cultures, VE in , we used only the SWHP surveillance cultures to estimate ρ kντ in equation (1) . To estimate VE ex , we added the non-SWHP culture data to the SWHP culture data to estimate ρ kντ in equation (1) . To get confidence intervals for VE ex , we bootstrap the external culture data separately, then add each external bootstrap dataset to the corresponding bootstrap dataset from the main SWHP data set to get the bootstrap estimate of the proportion of cultures that are positive. We then compute VE ex for the bootstrap data set. In using the external cultures, we make the assumption that the population producing the non-SWHP cultures is similar to the population producing the 
Sensitivity analysis on assumption about positive cultures
When spread over a ten week period, the culture data were too sparse to obtain a weekly estimate of ρ kντ for use in equation (1). So we used the overall estimated proportion positive in Table 4 in each group as the weekly estimate for the proportion positive in equation (1) . A sensitivity analysis explored the effect of assuming that the proportion of positive cultures was constant throughout the season. The data were too sparse to use any nonparametric or parametric smoothing method. We assumed a form for the change in the proportion of cultures over the ten week period that had a peak in the middle of the season and was lower on both ends, so that the total proportion of the positive cultures over the season equaled the observed overall proportion positve. We multiplied the vector (.70,.75,1,1.25,1.3,1.3,1.25,1,.75,.70) (which sums to 10) by the proportion positive in each age and vaccination group to obtain the estimated weekly proportion positive, {ρ kντ }. Then equation (1) was used to compute VE in or VE ex . Inference was based on bootstrap confidence intervals. The results assuming that the proportion positive varied over time were essentially identical to those in Table 5 . For example, the overall VE ex for LAIV-T in the sensitivity analysis was 0.56 (95% CI 0.33,0.75), the same as in Table 5 . Thus, assuming that the proportion of cultures that were positive was constant did not seem to influence the efficacy estimates VE in and VE ex . 
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